Diagnostic Surgery in India
Get Diagnostic Surgery at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Diagnostic Surgery in UAE
Diagnostic Surgery at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Diagnostic surgery for cancer — encompassing procedures such as excisional biopsy, incisional biopsy, laparoscopic staging, sentinel lymph node biopsy, and image-guided core-needle biopsy — is the definitive step that establishes histological diagnosis, determines tumour grade, and guides the entire oncology treatment roadmap. Across leading cancer centres in India and the UAE, diagnostic surgical procedures achieve tissue-diagnostic accuracy rates exceeding 95%, with minimally invasive approaches reducing hospital stay to as little as one to three days. GAF Healthcare connects international patients with JCI- and NABH-accredited oncology hospitals in India and JCI- and DHA-licensed centres in Dubai and Abu Dhabi, providing end-to-end coordination at a fraction of the cost patients would incur in North America or Western Europe.
Hospital Stay: 1–4 days (varies by procedure: percutaneous biopsy may be day-case; open surgical staging may require 3–4 inpatient days) • Total Stay in Country (Fit-to-Fly): 1–2 weeks (most minimally invasive diagnostic procedures: 7–10 days; open or laparoscopic staging procedures with drain removal: 10–14 days) • Success Rate: 95–98% diagnostic tissue-yield accuracy for image-guided and surgical biopsy techniques at high-volume oncology centres
What Is It?
Cancer diagnosis is a multi-step process, but it is the histopathological confirmation of malignant tissue — obtained through diagnostic surgery — that forms the irreplaceable cornerstone of oncology care. Diagnostic surgery encompasses a spectrum of procedures designed not to cure cancer, but to procure an adequate tissue sample for pathological, immunohistochemical (IHC), molecular, and genomic analysis. The resulting data — including tumour type, grade, receptor status (e.g., ER/PR/HER2 in breast cancer, PD-L1 expression in lung cancer, microsatellite instability in colorectal cancer), and mutational profile (EGFR, ALK, KRAS, BRCA1/2) — determines whether a patient is a candidate for surgery, chemotherapy, targeted therapy, immunotherapy, or a combination approach.
From a physiological standpoint, undiagnosed or misdiagnosed cancer results in delayed treatment initiation, inappropriate systemic therapy, and markedly worse survival outcomes. Staging procedures such as diagnostic laparoscopy or mediastinoscopy directly assess lymph node involvement and peritoneal spread, preventing unnecessary major resections in patients with disseminated disease and sparing them the morbidity of futile open surgery. Similarly, sentinel lymph node biopsy (SLNB) — now standard in early-stage breast cancer and melanoma — maps lymphatic drainage to identify the first echelon of nodes at risk, enabling accurate N-staging with minimal surgical trauma compared to complete axillary lymph node dissection.
The international standard of care, as defined by NCCN, ESMO, and ASCO guidelines, mandates that a tissue diagnosis be established prior to initiating any systemic or definitive local therapy, except in very specific emergency scenarios. Modern diagnostic surgical platforms — including robotic-assisted laparoscopic staging, fluorescence-guided SLNB with indocyanine green (ICG), and endobronchial ultrasound (EBUS)-guided mediastinal biopsy — have dramatically improved diagnostic precision while minimising morbidity. Both India and the UAE have adopted these technologies at their top-tier oncology institutions, supported by comprehensive molecular pathology laboratories capable of next-generation sequencing (NGS) turnaround within 10–14 working days.
Candidates
• Patients with a radiologically identified mass, nodule, or lymphadenopathy on CT, MRI, PET-CT, or mammography that is suspicious for malignancy but lacks tissue confirmation
• Individuals with elevated tumour markers (CA-125, CEA, AFP, PSA, CA 19-9) without a histologically confirmed primary site, requiring diagnostic surgery to identify the origin
• Patients presenting with unexplained ascites, pleural effusion, or peritoneal deposits where cytology alone is non-diagnostic, necessitating laparoscopic peritoneal biopsy or thoracoscopic pleural biopsy
• Patients with early-stage breast cancer, melanoma, or head-and-neck squamous cell carcinoma requiring sentinel lymph node biopsy (SLNB) for accurate N-staging prior to definitive surgery or radiation planning
• Individuals with suspected lymphoma (Hodgkin or non-Hodgkin) where a core-needle biopsy has been inconclusive and an excisional lymph node biopsy is required for architectural assessment
• Patients with mediastinal masses requiring mediastinoscopy, EBUS-TBNA, or VATS-guided biopsy to differentiate thymoma, lymphoma, germ cell tumour, or metastatic carcinoma
• Patients undergoing pre-treatment cancer staging via diagnostic laparoscopy to assess peritoneal carcinomatosis index (PCI) before planned cytoreductive surgery and HIPEC
• Required pre-procedure diagnostics: Full blood count, coagulation profile (PT/INR/aPTT), comprehensive metabolic panel, ECG, chest X-ray or CT chest, dedicated cross-sectional imaging of the suspected primary site (CT/MRI/PET-CT), tumour marker panel, and echocardiography if cardiothoracic procedures are planned
• Contraindications: Uncorrectable coagulopathy (INR >1.5 unless corrected), active systemic infection or sepsis, severe cardiopulmonary compromise (ASA Class IV–V) precluding general anaesthesia, inaccessible lesion anatomy without acceptable biopsy trajectory (relative contraindication — may require alternative access planning), and allergy to contrast agents if image-guided biopsy uses CT fluoroscopy or angiographic guidance (managed with premedication protocols)
Procedure
PERCUTANEOUS IMAGE-GUIDED BIOPSY (Minimally Invasive — First-line where feasible) Ultrasound-guided core-needle biopsy (CNB): Used for palpable or sonographically visible masses in the breast, thyroid, soft tissue, liver, and superficial lymph nodes. An 14–18 gauge automated biopsy gun acquires 3–5 cores; outpatient procedure under local anaesthesia with same-day discharge. Diagnostic accuracy >93% for breast lesions. CT-guided percutaneous biopsy: Preferred for deep-seated pulmonary nodules, retroperitoneal masses, bone lesions, and adrenal tumours. Coaxial biopsy technique allows multiple cores through a single pleural or peritoneal pass, reducing pneumothorax or haemorrhage risk. Accuracy for lung lesions: 90–95%. MRI-guided biopsy: Reserved for lesions only visible on MRI (e.g., MRI-only detected breast lesions, prostate lesions targeted via MRI-TRUS fusion biopsy using the UroNav or Artemis fusion platform). Multiparametric MRI (mpMRI) followed by targeted fusion biopsy has replaced random 12-core TRUS biopsy as the standard for clinically significant prostate cancer detection. Endoscopic ultrasound (EUS)-guided fine-needle aspiration/biopsy (FNA/FNB): Gold standard for pancreatic masses, submucosal GI lesions, and perigastric/perirectal lymph nodes. The 22–25 gauge FNA needle or 20–22 gauge FNB (Franseen/SharkCore) needle acquires tissue with rapid on-site evaluation (ROSE) by a cytopathologist to confirm adequacy. Endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA): Minimally invasive mediastinal staging tool replacing mediastinoscopy in most N2/N3 lung cancer staging scenarios. Provides real-time ultrasound guidance to biopsy mediastinal and hilar lymph node stations (2R, 2L, 4R, 4L, 7, 10, 11). Sensitivity for malignant mediastinal nodes: 89–93%.
SURGICAL BIOPSY TECHNIQUES (Open or Minimally Invasive) Excisional biopsy: Complete removal of a suspicious lymph node or small soft-tissue mass for intact architectural histopathological assessment. Preferred for suspected lymphoma where nodal architecture is diagnostically critical (Reed-Sternberg cells in Hodgkin lymphoma require intact follicular architecture). Performed under local or general anaesthesia. Incisional biopsy: Partial sampling of a large, unresectable mass; used for large sarcomas or unresectable tumours where the biopsy tract must be planned along the future resection axis to avoid tumour seeding of adjacent compartments. Sentinel Lymph Node Biopsy (SLNB): Current standard of care in early-stage breast cancer (T1-T2 N0) and melanoma. The sentinel node is identified using a dual-mapping technique combining 99mTc-labelled nanocolloid (radioisotope lymphoscintigraphy with gamma probe detection) and blue dye (patent blue or isosulfan blue), or increasingly with indocyanine green (ICG) fluorescence imaging using near-infrared (NIR) cameras (SPY-PHI or Fluobeam system). ICG-only mapping is now preferred at many centres due to superior visualisation and avoidance of radioactive material handling. Intraoperative frozen section or one-step nucleic acid amplification (OSNA) assay determines lymph node status within 30–40 minutes, permitting immediate axillary lymph node dissection (ALND) if macro-metastasis is confirmed. Diagnostic Laparoscopy with peritoneal washings: Critical staging procedure for gastric, ovarian, endometrial, and colorectal cancers before planned cytoreductive surgery or radical resection. The peritoneal carcinomatosis index (PCI) is scored laparoscopically across 13 abdominal regions (0–39 scale). PCI ≥20 in colorectal cancer or ≥10 in gastric cancer typically precludes curative resection. Peritoneal washings are sent for cytological analysis; positive cytology upstages gastric and ovarian cancer. VATS (Video-Assisted Thoracoscopic Surgery)-guided biopsy: Minimally invasive thoracoscopic approach for pleural biopsies, lung wedge resections (for indeterminate pulmonary nodules), and mediastinal mass biopsies not accessible via EBUS. Three 5–10 mm ports; hospital stay 2–3 days; significantly reduced morbidity versus open thoracotomy. Robotic-assisted staging procedures: The da Vinci Xi and Versius robotic platforms are used at premier centres in India (Tata Memorial, Apollo, Fortis) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai) for complex diagnostic staging laparoscopies, robotic mediastinal staging, and robotic-assisted SLNB in anatomically challenging cases. Advantages include 3D magnification, tremor filtration, and 540° EndoWrist articulation enabling precise dissection in confined anatomical spaces.
MOLECULAR AND GENOMIC PATHOLOGY (Post-Biopsy) All tissue obtained undergoes haematoxylin-and-eosin (H&E) histopathology plus IHC panel. Advanced centres offer next-generation sequencing (NGS) panels (e.g., FoundationOne CDx, Oncomine Dx Target Test, TruSight Oncology 500) for comprehensive genomic profiling, enabling identification of actionable mutations for targeted therapy (e.g., osimertinib for EGFR-mutant NSCLC, olaparib for BRCA-mutant breast/ovarian cancer, entrectinib for NTRK fusion-positive tumours). Liquid biopsy (circulating tumour DNA via Guardant360 or FoundationOne Liquid CDx) may complement but does not replace surgical tissue biopsy for initial diagnosis.
Cost of Diagnostic Surgery: India vs. UAE
The cost of diagnostic surgery for cancer varies significantly based on the specific procedure type (percutaneous biopsy, SLNB, diagnostic laparoscopy, VATS, EBUS), the extent of molecular pathology testing required (basic IHC vs. comprehensive NGS panel), the complexity of anaesthesia, and the hospital tier. India offers internationally accredited oncology care at 40–60% lower cost than the UAE, while the UAE provides proximity for patients from the Middle East, Africa, and Europe seeking premium infrastructure with shorter travel time. The figures below represent all-inclusive surgical package estimates (surgeon fees, anaesthesia, operating theatre, hospital stay, standard medications, and basic pathology); advanced NGS/molecular testing (an additional $500–$2,000 depending on panel) is quoted separately. GAF Healthcare provides fully itemised, written cost estimates before any commitment is made.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $1,200 – $5,500 | ~51% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $2,800 – $11,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PRE-OPERATIVE PHASE (Days 1–5 in destination country)
Day 1 — Arrival and Oncology Consultation: GAF Healthcare coordinates airport pickup and hotel check-in. The patient attends a consultation with the lead oncologist or surgical oncologist, who reviews all prior imaging (CT, MRI, PET-CT), pathology reports, and tumour marker data. The most appropriate diagnostic surgical approach is selected based on lesion location, accessibility, and required tissue volume for planned molecular testing.
Day 2–3 — Pre-Operative Investigations: Blood work (CBC, coagulation panel, metabolic panel, tumour markers), ECG, and anaesthesia fitness assessment are completed. For thoracic procedures, pulmonary function tests (PFTs) and echocardiography may be added. Anti-coagulants (warfarin, DOACs, aspirin) are bridged or held per protocol. Patients are counselled on the procedure, anaesthesia plan, and expected histopathology turnaround time.
Day 4 — Pre-Operative Day: Fasting from midnight (for GA procedures). Final imaging review by the interventional radiologist or surgeon. Surgical site marking and consent finalisation.
PROCEDURE DAY
Image-guided percutaneous biopsies: Performed under local anaesthesia ± conscious sedation in the interventional radiology suite. Duration 30–60 minutes. Patient observed for 2–4 hours post-procedure for pneumothorax (lung biopsies) or bleeding, then discharged.
Endoscopic/EBUS procedures: Performed under moderate sedation or GA; duration 45–90 minutes. Discharged same day or next morning.
SLNB / Excisional biopsy / Laparoscopic staging: Performed under general anaesthesia in a laminar-flow operating theatre. Duration 45 minutes (SLNB) to 2–3 hours (diagnostic laparoscopy with PCI scoring). Intraoperative frozen section or OSNA assay results communicated to the surgical team within 30–45 minutes. Patient transferred to surgical ward or day-surgery recovery.
VATS-guided biopsy / Mediastinoscopy: GA-based; duration 60–120 minutes. Chest drain inserted post-VATS and monitored for 24–48 hours before removal and discharge.
POST-OPERATIVE RECOVERY (In-Country)
Day 1–2 post-procedure: Pain managed with oral NSAIDs and paracetamol (opioids reserved for open or VATS cases). Drain sites checked; wound inspection. Pathology specimens dispatched to histopathology and molecular laboratory.
Day 3–7: For minimally invasive cases, patients are ambulatory and may return to the hotel. Suture or clip removal (if non-absorbable) at Day 7. Incision care instructions provided.
Day 7–10: Preliminary histopathology (H&E + IHC) results typically available within 5–7 working days. The oncologist delivers results in a structured consultation — either in person, or via a GAF Healthcare-facilitated telemedicine session if the patient has returned to the hotel. The multidisciplinary tumour board (MDT) reviews confirmed diagnosis and formulates the definitive treatment plan.
Day 10–14: Final molecular/NGS results available. A comprehensive treatment roadmap document is prepared and emailed to the patient's home oncologist. Fit-to-fly clearance is provided by the surgical team once the wound is healed, drain removed, and no post-procedure complications (e.g., pneumothorax, haematoma, infection) are present.
KEY RECOVERY MILESTONES
• Return to light activities: 24–48 hours (percutaneous biopsy), 3–5 days (SLNB/excisional biopsy), 5–7 days (laparoscopic staging/VATS)
• Driving: Not before 48 hours post-GA; typically 5–7 days
• Fit to fly (international): 7 days for percutaneous/endoscopic procedures; 10–14 days for laparoscopic, VATS, or open surgical procedures
• Return to normal physical activity: 2–4 weeks for laparoscopic/VATS procedures
• Molecular pathology results and treatment plan: Available within 10–14 working days of biopsy
Risks & Considerations
Diagnostic surgery for cancer carries procedure-specific risks that patients must understand before providing informed consent. For percutaneous image-guided biopsies, the most common complications are localised bleeding or haematoma (1–3%), pneumothorax following CT-guided lung biopsy (10–20%, the majority resolving without intervention; chest drain required in 1–2%), and needle-tract seeding of tumour cells (a rare but real risk in hepatocellular carcinoma and pleural mesothelioma biopsies, estimated at <0.1–0.3%, which is why biopsy approach planning must account for future resection axes). For SLNB, risks include lymphoedema of the arm (1–7% when fewer than three sentinel nodes are removed, markedly lower than the 20–30% risk with complete ALND), seroma formation at the axillary wound site (5–15%), wound infection (1–3%), and sensory nerve injury causing numbness or paraesthesia of the upper inner arm (intercostobrachial nerve). For diagnostic laparoscopy, risks include port-site complications (hernia or bleeding, <1%), inadvertent visceral injury to bowel or bladder (<0.5%), and the general anaesthesia risks stratified by ASA physical status classification (ASA I–II: <0.1% mortality; ASA III: 0.5–1%). VATS carries a risk of prolonged air leak (air escaping through chest drain for >5 days, requiring extended hospitalisation, occurring in 3–8% of cases), haemorrhage (1–2%), and conversion to open thoracotomy (1–3%). Patients on anticoagulation have a significantly elevated bleeding risk; bridging therapy protocols must be strictly followed. General anaesthesia risks — including aspiration, allergic reaction to induction agents, and post-operative nausea — are mitigated by pre-operative optimisation and experienced anaesthetic teams at accredited centres. Critically, a non-diagnostic or insufficient biopsy (occurring in 5–10% of cases at lower-volume centres vs. <3% at high-volume oncology institutions) necessitates repeat biopsy, delaying treatment initiation — one of the strongest arguments for choosing a high-volume, accredited cancer centre through GAF Healthcare.
Top Hospitals for Diagnostic Surgery
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Diagnostic Surgery
Internationally trained specialists in Surgical Oncology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Ashwin Sunil Tamhankar
MBBS, MS, MCh Urology, DNB Urology, Vattikuti Robotic Uro-oncology Fellowship, RCS Laser Urological Robotic Fellowship, Olympus Laparoscopic Endo-Urology Fellowship
Surgical Oncologist & Robotic Uro-Oncologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Ashwin Sunil Tamhankar is a Consultant in Surgical Oncology and Robotic Surgery based at Apollo Hospitals in Navi Mumbai, India. With over 9 years of specialized experience, he has established himself as a leading uro-oncologist, combining advanced robotic surgical techniques with precision cancer care. His credentials include MBBS, MS, MCh Urology, DNB Urology, and prestigious fellowships from the Vattikuti Institute, Royal College of Surgeons of… Read more
Dr. Asit Arora
MBBS, MS, MCh
GI & HPB Surgical Oncologist
Indraprastha Apollo Hospital, New Delhi, India
22+ Yearsof experience
Dr. Asit Arora is a Clinical Lead in GI and HPB Surgical Oncology at Indraprastha Apollo Hospital, New Delhi, bringing over 22 years of specialized expertise in managing complex gastrointestinal and hepatobiliary cancers. He holds an MBBS, MS in General Surgery, and an MCh in Gastrointestinal Surgery, and is widely recognized across India and internationally for his precision in radical oncologic resections and advanced abdominal cancer surgery. Dr. Arora… Read more
Dr. B. Niranjan Naik
MBBS, MS, Onco-Surgery, FIAGES
Surgical Oncologist
Paras Hospitals, Gurugram, India
22+ Yearsof experience
Dr. B. Niranjan Naik is Principal Director of Surgical Oncology and Director of Breast & Gastro-Intestinal Onco-Surgery at Paras Hospitals in Gurugram. With over 22 years of distinguished clinical experience, he is widely recognized as one of the leading breast cancer surgeons in the Delhi and Gurugram region. His credentials include MBBS and MS (General Surgery) from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by specialized… Read more
Dr. Belal Bin Asaf
MBBS, MS (Surgery), Fellowship in Thoracic Surgery, Certification as Robotic Console Surgeon, Observing Fellowship in VATS Lobectomy, Training in Minimally Invasive Esophagectomy
Thoracic Surgical Oncologist
Medanta — The Medicity, Gurugram, India
20+ Yearsof experience
Dr. Belal Bin Asaf is a distinguished Thoracic Surgical Oncologist and Director of Surgical Oncology at Medanta — The Medicity in Gurugram. With over 20 years of clinical experience, he has established himself as a pioneering leader in minimally invasive thoracic surgical oncology across India. His credentials include MBBS, MS in Surgery, Fellowship in Thoracic Surgery, and specialized certification as a Robotic Console Surgeon, combined with focused… Read more
Frequently Asked Questions — Diagnostic Surgery
The cost of diagnostic surgery for cancer varies by procedure type, complexity, and the extent of pathology testing requested. In India, at JCI- and NABH-accredited oncology centres, all-inclusive surgical packages range from approximately $1,200 to $5,500 USD. This range covers basic percutaneous image-guided biopsy under local anaesthesia (lower end) through to diagnostic laparoscopy with peritoneal washings, VATS-guided biopsy, or sentinel lymph node biopsy under general anaesthesia with standard immunohistochemistry (upper end). Advanced molecular testing such as next-generation sequencing (NGS) panels or liquid biopsy typically adds $500–$2,000 and is quoted separately. In the UAE (Dubai and Abu Dhabi), at JCI-accredited and DHA-licensed cancer centres, equivalent procedures range from approximately $2,800 to $11,000 USD — reflecting the UAE's premium infrastructure, internationally recruited surgical faculty, and higher operating costs. India is consistently 40–60% less expensive than the UAE for comparable oncology diagnostic procedures. GAF Healthcare provides fully itemised, written cost estimates for both destinations before any commitment, and helps patients choose the destination that best balances clinical quality, budget, and travel logistics.
The required in-country stay before you are safe to board an international flight depends on the specific diagnostic procedure performed. For percutaneous image-guided biopsies (CT-guided, ultrasound-guided, or MRI-guided core-needle biopsy) and endoscopic procedures such as EBUS-TBNA or EUS-FNB, most patients are fit to fly within 7 days of the procedure, once wound healing is confirmed and any post-procedure complications (such as pneumothorax after a lung biopsy) have been excluded with a follow-up chest X-ray. For surgical procedures performed under general anaesthesia — including sentinel lymph node biopsy (SLNB), excisional lymph node biopsy, diagnostic laparoscopy, or VATS-guided pleural or lung biopsy — a minimum of 10–14 days in-country is recommended. This allows time for wound healing, chest drain removal (if applicable), suture removal, and the preliminary histopathology results consultation so you do not depart without an initial understanding of your diagnosis. Your surgical team at the treating hospital will issue a formal fit-to-fly clearance letter, and GAF Healthcare coordinates the timing of your discharge, hotel stay, and departure flight accordingly. Patients with post-operative drains, unresolved pneumothorax, or active wound complications should not fly until these are fully resolved, as altitude-related pressure changes can worsen certain complications.
It is important to clarify that the term 'success rate' for diagnostic surgery refers to the diagnostic yield — the proportion of procedures that successfully obtain sufficient, high-quality tissue for definitive histopathological, immunohistochemical, and molecular analysis — rather than a cure rate, since diagnostic surgery is an investigative procedure rather than a therapeutic one. At high-volume, internationally accredited oncology centres in India and the UAE partnered with GAF Healthcare, diagnostic accuracy and tissue-yield success rates are as follows: CT-guided percutaneous core-needle biopsy achieves diagnostic adequacy in 90–95% of cases for pulmonary and deep-seated abdominal lesions; ultrasound-guided breast core-needle biopsy achieves >93% diagnostic accuracy; EBUS-TBNA for mediastinal lymph node staging has a sensitivity of 89–93% for malignant involvement; EUS-FNB for pancreatic masses achieves diagnostic adequacy in 85–93% of cases; and surgical excisional biopsy or SLNB, when performed by an experienced oncological surgeon, delivers a diagnostic success rate of 95–98%. Non-diagnostic or insufficient biopsies — the main 'failure' mode — occur in <3–5% of cases at high-volume centres (compared to 10–15% at lower-volume facilities), primarily driven by necrotic or fibrotic tumours, very small lesions (<8mm), or suboptimal sampling technique. In such cases, a repeat biopsy using an alternative approach (e.g., upgrading from CNB to surgical excision, or from EBUS to mediastinoscopy) is recommended. GAF Healthcare exclusively partners with centres that maintain audited, high-volume diagnostic oncology programmes, minimising the risk of a non-diagnostic result and unnecessary delay to your cancer treatment.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive non-medical coordination to ensure that international patients can focus entirely on their diagnosis and recovery, with every logistical detail managed by a dedicated case coordinator.
VISA ASSISTANCE — INDIA: GAF Healthcare facilitates the e-Medical Visa application for India, which covers the patient and up to two attendants (family members or caregivers). The e-Medical Visa is issued within 24–72 hours for most nationalities, permits a stay of up to 60 days per entry, and allows three entries within one year. GAF Healthcare provides the hospital invitation letter, estimated treatment cost letter, and all documentation templates required by the Indian High Commission or Embassy for the application.
VISA ASSISTANCE — UAE (DUBAI / ABU DHABI): Citizens of over 50 countries, including the EU, UK, USA, Canada, Australia, and GCC nationals, receive visa-free entry or visa-on-arrival for the UAE for up to 30–90 days depending on passport. For nationalities requiring a prior visa, GAF Healthcare coordinates a UAE medical or visit visa through the hospital's international patient centre, typically processed within 3–5 working days.
AIRPORT TRANSFERS: Private, air-conditioned vehicle transfers are arranged for arrival and departure for both the patient and their attendant — including accessible vehicles for patients with mobility limitations. For patients arriving with significant pain or post-procedural drainage requirements, trained medical escort staff can be arranged on request.
DEDICATED PATIENT COORDINATOR AND TRANSLATION: Each patient is assigned a named GAF Healthcare case coordinator who is available via WhatsApp, phone, and email from initial inquiry through final medical report delivery. Language interpreters covering Arabic, Russian, French, Swahili, Amharic, and other major languages are available for consultations, consent discussions, and pathology result reviews.
ACCOMMODATION FOR PATIENT AND ATTENDANT: GAF Healthcare has negotiated rates at partner hotels and serviced apartments within 1–3 km of all partner hospitals in Mumbai, Delhi, Chennai, Hyderabad, Dubai, and Abu Dhabi. Options range from standard 3-star accommodation ($30–$70/night in India; $80–$150/night in UAE) to 5-star medical suites ($120–$250/night in India; $250–$500/night in UAE). All partner accommodations are verified for cleanliness, dietary accommodation (including halal, vegetarian, and low-sodium options), and proximity to the treating hospital.
POST-DISCHARGE TELEMEDICINE: Once pathology results are available (typically Day 7–14), GAF Healthcare arranges a structured telemedicine consultation between the patient (now potentially back home) and the treating oncologist to discuss findings and the definitive treatment plan. A full medical summary report in English — including histopathology, IHC results, molecular findings, and NCCN/ESMO-aligned treatment recommendations — is couriered and emailed to the patient's home physician.
Patients Also Explore
Other treatments commonly sought by patients considering Diagnostic Surgery.
Breast Cancer Treatment
Cancer Care
Lung Cancer Treatment
Cancer Care
Colonoscopy & Polypectomy
Gastroenterology
Hepatitis B Treatment
Gastroenterology